Genprex to Present at NobleCon16 Investor Conference
February 03 2020 - 8:17AM
Business Wire
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company utilizing a unique, non-viral
proprietary platform designed to deliver tumor suppressor genes to
cancer cells, announced that the Company will present at the Noble
Capital Markets 16th Annual Investor Conference on Monday, February
17, 2020 at 1:30 p.m. EST. The conference is being held on February
16-18, 2020 at the Seminole Hard Rock Hotel & Casino in
Hollywood, Florida.
Event: NobleCon16 - Noble Capital
Markets’ 16th Annual Investor Conference
Presentation Date: Monday, February
17, 2020
Presentation Time: 1:30 p.m. EST –
Terrace Ballroom A
Location: Seminole Hard Rock Hotel
& Casino – Hollywood, FL
Mr. Rodney Varner, Chief Executive Officer of Genprex, will
deliver an overview of the Company and provide updates on its
product pipeline, including the recent Fast Track Designation
received from the Food and Drug Administration for its Oncoprex™
immunogene therapy in combination with AstraZeneca’s Tagrisso®. To
arrange a one-on-one meeting with the Company, please email
investors@genprex.com.
A high-definition video webcast of Mr. Varner’s presentation
will be available for playback at the link below approximately 24
hours following his live address, and it will be archived for 90
days following the conference:
Presentation Webcast Playback:
http://bit.ly/2S5AR7Z
This is the 16th year Noble Capital Markets has hosted
“NobleCon” and has invited emerging growth companies to present to
and meet with attending investors. NobleCon will feature
approximately 125 small growth companies presenting across four
tracks and will be broadening access to investors worldwide by
hosting the conference site on Channelchek.com, its web-based
market platform that emphasizes emerging growth companies.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer
patients based upon a unique proprietary technology platform.
Genprex’s platform technologies are designed to administer
cancer-fighting genes by encapsulating them into nanoscale hollow
spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express
proteins that are missing or found in low quantities. The company’s
lead product candidate, Oncoprex™ immunogene therapy for non-small
cell lung cancer (NSCLC), has a multimodal mechanism of action
whereby it has been shown to interrupt cell signaling pathways that
cause replication and proliferation of cancer cells, re-establish
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulate the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. In
January 2020, the FDA granted Fast Track Designation for Oncoprex™
immunogene therapy for NSCLC in combination therapy with
AstraZeneca’s Tagrisso®. For more information, please visit the
company’s web site at www.genprex.com or follow Genprex on Twitter,
Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex, or Oncoprex in combination with
immunotherapies, and Oncoprex combined with immunotherapies and
chemotherapies, on cancer, as well as the potential benefits of
Fast Track Designation to us. Risks that contribute to the
uncertain nature of the forward-looking statements include risks
relating to the presence and level of the effects of Oncoprex,
alone and in combination with immunotherapies and chemotherapies,
on cancer, the safety and effectiveness of Oncoprex, alone and in
combination with immunotherapies and chemotherapies, as well as the
timing and success of our clinical trials and planned clinical
trials of Oncoprex™ and our other potential product candidates.
Other risks and uncertainties associated with Genprex and its lead
product candidate Oncoprex are described more fully under the
caption “Risk Factors” and elsewhere in our filings and reports
with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200203005040/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024